Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,010,000 shares, a growth of 11,509.2% from the March 31st total of 8,700 shares. Based on an average daily volume of 6,220,000 shares, the short-interest ratio is presently 0.2 days. Approximately 26.7% of the shares of the company are short sold.

Adial Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:ADIL opened at $1.73 on Friday. The company has a market cap of $7.02 million, a price-to-earnings ratio of -0.30 and a beta of 1.48. The business has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.81. Adial Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $14.00.

Institutional Investors Weigh In On Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 159,000 shares of the company’s stock, valued at approximately $296,000. Armistice Capital LLC owned about 9.58% of Adial Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.